$PFE shareholders are the ones who benefit most from this deal.
$PFE shareholders are the ones who benefit most from this deal. Blackstone covers up to $1.5B of obesity-drug development costs through 2028 and gets paid only if berobenatide clears the FDA and hits sales targets.
- Pfizer and Blackstone Life Sciences announced the agreement on November 11, 2026. Blackstone-managed funds pay up to $1.5B of development costs for berobenatide, an investigational monthly GLP-1 receptor agonist peptide.
- Pfizer keeps full operational control and decision-making. Blackstone gets no ownership and no drug rights, only milestone payments tied to U.S. approval as a monthly weight-management monotherapy plus specified sales milestones. Payment amounts were not disclosed.
- The program is big and still early-stage risk: Pfizer says its 2026 plan includes 10 ongoing and planned Phase 3 trials. Trial data is the binary event in biotech, and Blackstone now carries part of that bill.
- The market barely moved. PFE was $29.50 after-hours, up 0.17% from a $29.45 close.
My read is that Pfizer gets to stay in the obesity race while protecting cash for the rest of its pipeline, and Blackstone is the one exposed if the trials disappoint. Since the milestone terms weren't disclosed, I could be wrong about how much upside Pfizer gives away. Will more pharma companies start handing their trial risk to private capital?
Sources:
Reuters: Pfizer secures up to $1.5B from Blackstone for obesity drug development: https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-secures-up-15-billion-blackstone-obesity-drug-development-2026-11-11/
Pfizer/Blackstone: Strategic Funding Agreement for Obesity Program: https://www.businesswire.com/news/home/20261111068291/en/Pfizer-and-Blackstone-Life-Sciences-Announce-Strategic-Funding-Agreement-for-Obesity-Program/
Not financial advice. For informational and educational purposes only.
8.8%. That's Oracle's November 11 close, and what I care about more is that the CFO says its major data-center projects are already…
8.8%. That's Oracle's November 11 close, and what I care about more is that the CFO says its major data-center projects are already under construction. A one-day pop tied to a peer's earnings won't move my AI capex view much, but building that's already underway is a better…
NVDA has been under pressure for days over the board's investigation into reports that Jensen Huang was targeted by a foreign…
NVDA has been under pressure for days over the board's investigation into reports that Jensen Huang was targeted by a foreign intelligence effort. Today Reuters added a sanctions story on top of it, and the stock still closed up 2.79% at $173.61. It had been up as much as 5.12% intraday before giving some of that back.
Oil Shocks 1973 vs 2026 — Same Shock, Different Inflation
In October 1973, the NYT ran a telling headline: "Six Oil Countries Raise Price 17%." That was the start of the Arab oil embargo, and oil didn't…
In October 1973, the NYT ran a telling headline: "Six Oil Countries Raise Price 17%." That was the start of the Arab oil embargo, and oil didn't stop at 17%. Posted U.S. crude prices ran from roughly $3 a barrel to about $12 during the 1973–74 shock, then to $35 by 1980. U.S. CPI inflation peaked at 14.8% in March…
Afternoon update
One earnings report repriced the AI infrastructure trade on November 11.
One earnings report repriced the AI infrastructure trade on November 11. CoreWeave's Q3 beat and raised guidance lifted the neocloud and semiconductor names behind it. $NBIS Nebius Group rose 18.91% to a $38.0B market cap in a sympathy move…